Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 27, 2024 08:30 ET | Source: Wave Life Sciences USA, Inc.

Wave Life Sciences Announces Upcoming Presentations at MDA Conference that Highlight Best-in-Class Potential for WVE-N531 in Duchenne Muscular Dystrophy

Presentations include data for WVE-N531 that provide first clinical evidence of a potential therapeutic for DMD accessing satellite cells, which are important for potential muscle regeneration ...
May 16, 2023 06:00 ET | Source: Locanabio, Inc.

Locanabio Presents Preclinical Data from its Vectorized snRNA Exon Skipping Program for DMD and Cas13d Multi-targeting Program for C9orf72 ALS at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting

LBIO-115 demonstrates robust exon 51 skipping resulting in high levels of dystrophin restoration in patient-derived muscle cells and an in vivo DMD disease model Cas13d Multi-targeting efficiently...
February 16, 2022 05:35 ET | Source: Vantage Market Research

Global Dystrophin Market to Reach USD 30.22 Billion by 2028 - Heavy Research & Development to Boost the Market Demand – Vantage Market Research

WASHINGTON, Feb. 16, 2022 (GLOBE NEWSWIRE) -- The Global Dystrophin Market size is expected to reach USD 30.22 Billion by 2028, exhibiting a Compound Annual Growth Rate (CAGR) of 45.9% during the...
September 08, 2014 08:00 ET | Source: Prosensa Holding N.V.

Prosensa announces Lancet Neurology publication of an exploratory phase II study (DEMAND II) demonstrating efficacy and safety of drisapersen in patients with Duchenne muscular dystrophy

Leiden, The Netherlands, Sept. 8, 2014 (GLOBE NEWSWIRE) -- LEIDEN, The Netherlands - September 8, 2014 - Prosensa Holding N.V. (NASDAQ: RNA), the biopharmaceutical company focusing on RNA-modulating...
June 27, 2014 08:00 ET | Source: Prosensa Holding N.V.

Prosensa Awarded $200,000 Research Grant from PPMD

Leiden, The Netherlands, June 27, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA), the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high...
May 13, 2014 08:57 ET | Source: Prosensa Holding N.V.

Prosensa Holding N.V. to Webcast Conference Call Discussing 1st Quarter 2014 Financial Results and Corporate Update on May 20, 2014

Leiden, The Netherlands, May 13, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA) today announced that the Company will host a conference call and live audio webcast on Tuesday, May 20,...
February 21, 2012 13:34 ET | Source: CureDuchenne

Cure Duchenne Announces Three New Funded Research Projects to Help Develop Treatments and Find a Cure for Duchenne Muscular Dystrophy

Newport Beach, Calif., Feb. 21, 2012 (GLOBE NEWSWIRE) -- CureDuchenne, a nonprofit organization that raises awareness and funds multiple research and development projects to cure Duchenne muscular...